Welcome to our dedicated page for Io Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on Io Biotech stock.
IO Biotech, Inc. (Nasdaq: IOBT) is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. This news page aggregates company announcements, clinical updates, financial disclosures, and regulatory communications related to IO Biotech and its lead investigational cancer vaccine candidate, Cylembio® (IO102-IO103).
Readers can find coverage of clinical trial milestones, including data from the pivotal Phase 3 IOB-013/KN-D18 trial of Cylembio plus KEYTRUDA® (pembrolizumab) in advanced melanoma and Phase 2 basket trials in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and other solid tumors. News items also highlight long-term outcomes from earlier-phase studies, such as the MM1636 Phase 1/2 trial, and pre-clinical data for additional T-win platform candidates IO112 and IO170.
Investors and followers of IOBT can review regulatory and corporate updates, including the company’s reports on FDA interactions regarding Cylembio, workforce restructuring plans, and participation in major medical and investor conferences. Financial press releases provide quarterly results, operating expense trends, cash position commentary, and details on financing arrangements such as the European Investment Bank term loan facility and associated warrants.
This page is useful for tracking how IO Biotech communicates progress on its immune-modulatory cancer vaccine programs, interprets key efficacy and safety results, and describes its ongoing engagement with regulators and collaborators. For those monitoring IOBT stock or the broader immuno-oncology field, the news feed offers a centralized view of the company’s scientific presentations, trial readouts, and strategic business developments over time.
IO Biotech announced key developments in its clinical trials and financial performance for Q3 2022. The global Phase 3 trial of IO102-IO103 with KEYTRUDA® has seen a significant increase in site activations, from 19 to 55 over three months, indicating strong patient enrollment potential. The Phase 1/2 study reports a median overall survival of 46.8 months and a complete response rate of 50%. The company ended the quarter with $151.2 million in cash, ensuring funding for upcoming data readouts into mid-2024. However, net losses for the quarter increased to $16.1 million.
IO Biotech (Nasdaq: IOBT) announced a fourth clinical trial collaboration with Merck to evaluate IO102-IO103 combined with KEYTRUDA® in patients with resectable tumors. This multicenter trial aims to assess anti-tumor activity and safety in neoadjuvant and adjuvant settings. The study will investigate pathologic tumor response and overall survival. IO Biotech holds global rights for IO102-IO103, which has shown early clinical promise in melanoma. The company is also conducting a Phase 3 trial for first-line melanoma treatment with KEYTRUDA®.
IO Biotech (Nasdaq: IOBT) announced that CEO Mai-Britt Zocca, Ph.D., and CFO Amy Sullivan will participate in the Jefferies London Healthcare Conference from November 15-17, 2022. They will discuss the company's innovative cancer therapies based on the T-win® technology platform and provide updates on the lead program IO102-103, currently in Phase 3 for metastatic melanoma. Early data from a Phase 2 study is expected by year-end. The fireside chat is scheduled for November 15, 2022, from 7:25-7:55 a.m. EST.
IO Biotech (Nasdaq: IOBT) appointed Amy Sullivan as its new Chief Financial Officer. With over 25 years in the life sciences sector, Sullivan's expertise includes capital raising and corporate management. She previously served as CFO at TABA and played a critical role at Kiadis Pharma, overseeing fundraising and the company's sale to Sanofi. President Mai-Britt Zocca expressed confidence in Sullivan's ability to contribute to the company's growth and promising pipeline of cancer immunotherapies, particularly leveraging the T-win technology platform.
IO Biotech (Nasdaq: IOBT) announced its participation in the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022) from November 8-12, 2022. The company will present an oral update on its Phase 1/2 study (MM1636) involving IO102-103 and nivolumab for metastatic melanoma. This study has led to FDA Breakthrough Therapy Designation for a subsequent Phase 3 trial with pembrolizumab. Additionally, two poster presentations will showcase preclinical data on new candidates targeting Arginase 1 and TGF-β1.
On September 6, 2022, IO Biotech (Nasdaq: IOBT) announced that President and CEO Mai-Britt Zocca will participate in a fireside chat and investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference from September 12 to 14, 2022. The fireside chat is scheduled for September 14 at 8:35 a.m. ET. Investors can access the webcast via the provided link, and a replay will be available for 180 days on the company’s website. IO Biotech is focused on developing immune-modulating cancer therapies using its T-win® technology platform.
IO Biotech initiated its Phase 3 trial combining IO102-IO103 with KEYTRUDA® as a first-line treatment for advanced melanoma, also starting a Phase 2 basket trial. Recent ASCO presentations highlighted promising results in ongoing trials. Financially, the company reported a Q2 net loss of $18.5 million, which is an improvement from $38.4 million a year earlier. R&D expenses rose to $12.2 million, driven by increased clinical activities. With $170.1 million in cash, IO Biotech has sufficient runway to support operations through mid-2024.
IO Biotech (Nasdaq: IOBT) will participate in the 2022 BIO International Convention from June 13-16 in San Diego, California. Chief Scientific Officer Muhammad Al-Hajj, Ph.D., will present a panel discussion titled "Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking" on June 13 at 1:00 pm local time. IO Biotech is focused on developing immune-modulating cancer therapies using its T-win® technology platform, including its lead candidate, IO102-IO103, targeting IDO and PD-L1.
IO Biotech (Nasdaq: IOBT) announced two poster presentations at the ASCO Annual Meeting 2022, showcasing clinical trials involving its investigational agent IO102-IO103 in combination with pembrolizumab for metastatic solid tumors and melanoma. The first is a Phase 3 trial on untreated, unresectable melanoma, while the second is a Phase 2 study targeting metastatic non-small cell lung cancer and other cancers. IO102-IO103 aims to counter immunosuppressive mechanisms through IDO and PD-L1 targeting. The presentations will occur from June 5-6, 2022, in Chicago.
IO Biotech (Nasdaq: IOBT) announces participation in the Jefferies Global Healthcare Conference scheduled for June 8-10, 2022, in New York City. CEO Mai-Britt Zocca will hold one-on-one investor meetings and present on June 8, 2022, from 8:30 to 8:55 a.m. ET. A live webcast of the presentation can be accessed through the company’s website. IO Biotech focuses on developing immune-modulating cancer therapies utilizing its T-win® technology platform. A replay of the presentation will be available for 90 days post-conference.